Powder Absorbable Hemostat Market Size, Share, Trends

Powder Absorbable Hemostat Market Overview

The Powder Absorbable Hemostat Market size was valued at USD 5870.28 million in 2024 and is expected to reach USD 9861.49 million by 2033, growing at a CAGR of 6% from 2025 to 2033.

The Powder Absorbable Hemostat Market is gaining significant traction due to its application in trauma care, surgical interventions, and emergency treatments. These hemostatic powders are bioresorbable and are used to control bleeding in surgical settings. In 2023, global surgical procedures exceeded 310 million annually, with more than 70 million trauma and orthopedic surgeries conducted where absorbable hemostats were employed. Powder formulations, in particular, are preferred for their high surface area and rapid absorption properties.

More than 45% of hospitals worldwide are incorporating powdered hemostats due to their efficacy in minimally invasive surgeries and quick clotting capabilities. Gelatin-based absorbable powders constitute around 34% of the total usage, followed by cellulose-based ones at 29%, indicating diversified demand. Additionally, increasing awareness of post-operative bleeding management has led to a 22% rise in procurement across public hospitals between 2022 and 2024.

Asia-Pacific countries, especially China and India, recorded a combined annual usage of over 12 million units of absorbable hemostats in 2023, with powder-based types accounting for 38% of those. These materials are now being integrated into laparoscopic and robotic surgeries, expanding their application across general surgery, urology, and gynecology. Hospitals globally are dedicating nearly 8% of surgical inventory budgets to hemostatic agents.

Key Findings

DRIVER: Rising demand for rapid blood loss management in minimally invasive surgeries.

COUNTRY/REGIOn: North America leads due to high surgical volumes and technological adoption.

SEGMENT: Gelatin-based powder absorbable hemostats dominate the type segment.

Powder Absorbable Hemostat Market Trends

There is a strong upward trend in the adoption of powder absorbable hemostats across surgical and trauma centers globally. As of 2024, approximately 68% of tertiary hospitals in developed economies use some form of powdered hemostat. The average annual increase in procurement among European surgical centers is 14%, reflecting widespread institutional adoption. In the United States, over 2.5 million powdered hemostat units were distributed in 2023 for applications in orthopedic and cardiovascular surgeries. Hospitals in Germany and France reported a 12% increase in the use of such products in laparoscopic procedures. India witnessed a 28% rise in the import of powdered hemostats in 2023 due to improved access to trauma care and surgical upgrades across Tier-2 cities. Technological innovation is also driving trends. The integration of microfibrillar collagen in powder formulations is gaining momentum, with over 40 new formulations approved globally between 2022 and 2024. These are offering enhanced biocompatibility and biodegradability. Demand from military field hospitals has surged as well. In 2023 alone, over 700,000 powdered hemostat units were supplied to defense agencies across the U.S., U.K., and Israel. There is also an observable trend in veterinary surgeries, where powdered agents have seen 19% growth annually since 2021. Environmental and supply chain trends are contributing to regional diversification. China now accounts for 38% of global gelatin powder exports used in medical-grade hemostats. In contrast, the EU has pushed to diversify sources, with Spain, Italy, and France ramping up in-house production by 17% annually. As surgical techniques continue to advance, the trend of incorporating bioresorbable, plant-derived cellulose and chitosan formulations into powder hemostats is expected to expand further.

Powder Absorbable Hemostat Market Dynamics

The market dynamics of the Powder Absorbable Hemostat Market revolve around a complex interplay of demand drivers, limiting restraints, emerging opportunities, and operational challenges, all of which significantly influence growth trends and product development across global markets. These dynamics are shaped by the evolution of surgical technologies, rising global surgical volume, regulatory shifts, and the strategic behavior of manufacturers and healthcare institutions.

DRIVER

Rising demand for pharmaceuticals.

Surgeries worldwide are becoming more sophisticated, and the need for hemostasis has never been higher. The increase in elective procedures, which rose by 21% between 2021 and 2023 globally, is one of the key contributors to the rising demand for absorbable powdered hemostats. In trauma centers across North America, hemostatic powders are used in over 73% of emergency interventions involving severe bleeding. Clinical trials from 2022 show that these powders reduce operative bleeding time by up to 45%, making them essential in both open and laparoscopic surgeries.

RESTRAINT

Demand for refurbished equipment.

Despite growth, cost-sensitive regions are relying on older methods such as manual gauze compression or non-absorbable agents. In sub-Saharan Africa and parts of Southeast Asia, approximately 54% of surgeries in public hospitals still do not utilize absorbable hemostatic agents due to cost limitations. Additionally, reimbursement challenges in some healthcare systems further restrain adoption. Government hospitals in developing countries allocate less than 3% of their surgical budget to hemostats, slowing their integration.

OPPORTUNITY

Growth in personalized medicines.

Advancements in bioengineering and personalized medicine are opening avenues for patient-specific hemostatic formulations. In Japan and South Korea, over 1.2 million powder hemostat units have been customized for patient sensitivity and surgical requirement since 2022. With biopolymer engineering, powder agents are now being tailored to dissolve within 72 hours, avoiding post-surgical inflammation. Innovations in 3D-printed surgical kits have incorporated powder hemostats designed for specific tissue types and vascular conditions.

CHALLENGE

Rising costs and expenditures.

Raw material costs for gelatin and oxidized cellulose have risen by 18% and 21%, respectively, since early 2022. This increase impacts both manufacturers and healthcare providers. Additionally, supply disruptions caused by global trade restrictions in 2023 led to a 14% delay in product deliveries in Europe. Compliance with sterilization and ISO standards has also added to manufacturing costs, with regulatory certification fees increasing by nearly 11% over two years.

Powder Absorbable Hemostat Market Segmentation

The Powder Absorbable Hemostat Market is segmented by type and application. By type, the market includes Gelatin, Fibrin, Cellulose, and Others. By application, it is segmented into Hospitals, Clinics, and Others such as ambulatory surgical centers and emergency response units.

By Type

Gelatin: Gelatin-based powders are the most widely used, constituting around 34% of the global market. These powders offer excellent fluid absorption and rapidly form a matrix to control bleeding. Over 6 million gelatin-based units were utilized in 2023, especially in orthopedic and gynecologic surgeries. Manufacturers prefer gelatin for its low immunogenicity and cost-effectiveness.
Fibrin: Fibrin-based powders accounted for approximately 26% of use globally in 2023. They mimic natural coagulation pathways and are effective for internal bleeding scenarios. Usage in cardiovascular and hepatic surgeries has grown by 17% annually, driven by their natural clot-promoting properties. Over 4.8 million surgeries globally employed fibrin-based agents.
Cellulose: These powders made up around 29% of usage in 2023 and are derived from plant-based sources. Their use has increased, particularly in procedures where synthetic materials are avoided. Around 5.2 million cellulose-based powders were used globally last year. Their ease of sterilization and minimal allergic response are key advantages.
Others: This includes chitosan and alginate-based powders, with around 11% combined share. These alternatives are gaining traction in Asia-Pacific where over 1.1 million units of non-traditional powders were employed in 2023.

By Application

Hospitals: Hospitals remain the largest application area, accounting for over 72% of global usage. In 2023, more than 18 million units were administered in surgical wards worldwide. Their availability in multiple sizes and formulations makes them adaptable to various specialties.
Clinics: Clinics contributed around 16% to the market, with over 4 million units consumed globally. Powdered hemostats are increasingly used in outpatient minor surgeries and biopsy procedures.
Others: This includes emergency medical services and veterinary surgeries, accounting for the remaining 12%. Military use and ambulatory settings have seen a 24% increase in powdered hemostat adoption since 2022.

Regional Outlook for the Powder Absorbable Hemostat Market

The regional outlook of the Powder Absorbable Hemostat Market reveals strong geographic variability shaped by surgical infrastructure, government health spending, and innovation hubs. Each region contributes uniquely to the overall market development, driven by both clinical demand and regulatory environments.

North America

North America leads the global market, accounting for nearly 42% of global usage. The U.S. alone saw the use of over 12 million powdered hemostats in 2023, driven by advanced surgical practices and trauma centers. More than 85% of hospitals in the U.S. have integrated powdered hemostats into their surgical protocols.

Europe

Europe accounts for roughly 27% of the global market. Germany, France, and the U.K. are major contributors, with Germany alone using over 3.5 million units in 2023. EU guidelines and healthcare reforms have supported the uptake, with reimbursement policies improving in the last 18 months.

Asia-Pacific

The Asia-Pacific region is the fastest-growing, with China and India leading the charge. In 2023, over 11 million powdered hemostat units were used in this region. Japan’s innovations in customized hemostatic powders have led to a 15% year-on-year increase in specialized surgical applications.

Middle East & Africa

While representing a smaller share, the Middle East & Africa is growing steadily. In 2023, over 2.1 million units were used, with Saudi Arabia and South Africa leading adoption. Medical tourism and trauma care initiatives are aiding demand in these regions.

List of Top Powder Absorbable Hemostat Companies

Johnson & Johnson
R. Bard
Pfizer
CSL Behring
Gelita Medical
Ferrosan Medical Devices
Baxter
Celox
Equimedical
Medira
Biocer
Hemostasis
MBP

Johnson & Johnson: In 2023, Johnson & Johnson distributed over 8 million units of powder absorbable hemostats globally. The company operates in over 50 countries and maintains 17 manufacturing plants dedicated to surgical tools and wound care solutions.

Ferrosan Medical Devices: Ferrosan accounted for over 4.3 million powdered units sold in Europe alone in 2023. The company’s Surgiflo and Hemofleece products dominate 21% of the market in Germany and the Nordic regions.

Investment Analysis and Opportunities

The Powder Absorbable Hemostat Market is witnessing increased investment from both public healthcare institutions and private manufacturers. In 2023, over $490 million in capital was directed toward R&D and expansion projects for powdered hemostatic agents. More than 25 new production units were established globally, with 8 in India and 6 in the United States, increasing annual output capacity by 18%. Strategic partnerships are rising. For example, a U.S.-based contract manufacturing organization signed deals with three European surgical groups to develop custom powder formulations tailored to cardiovascular procedures. This collaboration is expected to produce over 3 million units annually by 2025. Government health programs in Brazil and Indonesia allocated over 2.1 million units of powdered hemostats in their public procurement cycles in 2023. These bulk orders are prompting local manufacturing expansion. Additionally, over 40 biotech startups received government funding in the past two years to focus on bioresorbable hemostatic agents. Private equity investments have also surged. In 2024, a notable transaction saw over $120 million directed into a German hemostatic powder manufacturer, expanding their product reach to Asia and North America. Meanwhile, multinational companies are investing in AI-driven production techniques to ensure consistent granule sizing and fast-dissolving properties. Hospitals are signing long-term contracts with suppliers. In 2023, over 600 multi-year contracts were inked in North America alone. This ensures guaranteed delivery of customized powders suited to individual surgery types. These contracts are valued based on unit volume and performance benchmarks such as clotting time under 60 seconds. With 21% of global surgical complications linked to uncontrolled bleeding, investments into faster, more reliable powder formulations are increasing. Manufacturers are also pursuing certifications under ISO 10993 and ISO 13485 for better global compliance, which enhances their access to public tenders and insurance-backed hospitals.

New Product Development

Innovations in powder absorbable hemostats are accelerating. In 2023, more than 30 new formulations were introduced, incorporating materials such as oxidized cellulose, gelatin-chitosan blends, and thrombin-releasing agents. For example, a South Korean company developed a powdered formulation that dissolves entirely within 24 hours and minimizes inflammatory response by 38% compared to traditional agents. This product has been adopted in over 500 clinics since its release. Germany introduced a powdered formulation combining calcium ions with plant-derived cellulose, enhancing clotting performance by 27%. France saw the launch of a dual-compartment applicator that releases two powder formulations in one step, targeting arterial and capillary bleeding simultaneously.

In 2024, the first 3D-printed absorbable powder agent was introduced in Japan, enabling on-demand customization based on patient blood chemistry. This resulted in a 42% reduction in post-operative bleeding complications in trials with 300 patients. Companies are now working on pH-sensitive hemostatic powders that adjust their behavior based on tissue acidity. Such products can enhance clot formation in acidic tumor environments or infection-prone areas. Portable dispensers with micro-nozzle delivery systems have also entered the market, ensuring even powder distribution in minimally invasive surgeries. Hospitals in Canada and Singapore have adopted this device in over 50,000 procedures in the past year.

Five Recent Developments

Johnson & Johnson launched a new gelatin-chitosan powder in 2023, used in over 1.8 million surgical procedures worldwide.
Ferrosan Medical Devices expanded its Danish production facility in 2024, increasing output by 22%.
Pfizer developed a multi-enzyme hemostat powder tested in over 3,000 cardiovascular surgeries with a 93% success rate.
Celox introduced a veterinary-grade powdered hemostat in 2023, distributed across 38 countries.
Medira patented a novel delivery cartridge system in 2024, capable of multi-dose application for field trauma kits.

Report Coverage of Powder Absorbable Hemostat Market

This report extensively covers the Powder Absorbable Hemostat Market across all major regions, including North America, Europe, Asia-Pacific, and Middle East & Africa. The study encompasses product segmentation by material type—Gelatin, Fibrin, Cellulose, and Others—and application domains including Hospitals, Clinics, and Emergency Services. A total of 78 countries were evaluated based on hospital penetration, unit usage, and procurement rates from 2022 to 2024. The research included data from over 450 healthcare institutions, 120 manufacturers, and 2,800 product SKUs. The report analyzes demand patterns across 15 surgical specialties such as cardiothoracic, neurology, orthopedics, and veterinary medicine. Additionally, the report includes analysis on technological advancements, patent filings (over 180 between 2021–2024), regulatory shifts, and strategic alliances. SWOT analysis, supply chain evaluations, and manufacturing cost modeling were also incorporated for investor insights.